查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494760

表皮生長因子受體 (EGFR) 抑制劑到 2030 年的全球市場預測：按類型、藥物類型、給藥方法、分銷管道、應用、最終用戶和地區進行分析

Epidermal Growth Factor Receptor Inhibitors Market Forecasts to 2030 - Global Analysis By Type, Drug Type, Mode of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2024年全球表皮生長因子受體（EGFR）抑制劑市場規模將達141億美元，預測期內複合年成長率為14.2%，預計2030年將達314億美元。

表皮生長因子受體 (EGFR) 抑制劑是一種針對錶皮生長因子受體（一種存在於細胞表面的蛋白質）的藥物。 EGFR 參與細胞生長和分裂，其過度活性與某些癌症，特別是肺癌和大腸癌的發生和進展有關。 GFR 抑制劑可單獨使用或與化療或放射線治療等其他癌症治療方法合併用於治療多種癌症。

據美國國立衛生研究院稱，近年來，美國各類主要癌症的新病例顯著增加，包括肺癌、大腸直腸癌和乳腺癌。 2020年，美國預計將有180萬人被診斷出罹患癌症，606,520人將死於該疾病。

擴大標靶治療的採用

市場正在經歷標靶治療的快速採用，反映了不斷變化的治療模式。標靶治療透過特異性針對癌細胞並最大限度地減少對健康組織的損害來提高抗癌的精確度。這種模式轉移是由研究和開發的進步以及對促進癌症進展的分子途徑的深入了解所推動的。隨著個人化治療方法普及普遍，隨著對個別患者的個人化治療的轉變，市場有望實現顯著成長。

替代治療的可用性

市場面臨著適應替代療法的挑戰。儘管 EGFR 抑制劑有效，但免疫療法和標靶治療等替代療法正在相互競爭。此外，EGFR 抑制劑的抗藥性和副作用也增加了複雜性。確保替代療法的可用性、可負擔性和患者意識仍然是重要的障礙。市場必須適應，將這些治療方法整合到治療方案中，並滿足患者的特定需求以獲得最佳結果。

癌症發生率上升

市場上有一個令人擔憂的趨勢：癌症發生率上升。儘管Erlotinib和Gefitinib等 EGFR 抑制劑的治療取得了進展，但依賴這些療法的癌症病例的發生率仍在增加。這可能表明 EGFR 誘發的癌症盛行率增加，或者先前對這些藥物有反應的患者可能出現抗藥性。這些趨勢凸顯了繼續研究癌症生物學和開發創新治療策略的必要性。

昂貴的治療費用

該市場面臨著治療成本高昂的挑戰，為患者的取得造成了障礙。儘管它們在治療某些癌症方面有效，但抑制劑的經濟負擔限制了它們的普及。這個成本因素凸顯了相關人員需要共同努力開發更便宜的選擇並探索津貼途徑，以確保公平地獲得挽救生命的治療。

COVID-19 的影響：

COVID-19 的爆發對市場產生了重大影響，擾亂了製造、供應鏈和臨床試驗。關閉和限制阻礙了患者進入醫療機構，影響了診斷和治療的開始。然而，隨著遠端醫療和遠端監控的引入，保持了一定的連續性。市場出現了需求波動，並轉向優先考慮基本治療。儘管面臨挑戰，但持續的研究和開發旨在在大流行的挑戰中滿足新的需求並最佳化治療結果。

預計聯合治療領域在預測期內將是最大的。

預計聯合治療領域在預測期內將是最大的。透過同時針對多個途徑，這些療法旨在提高療效並克服抗藥性機制。 EGFR 抑制劑與化療、免疫療法和其他標靶藥物的聯合治療正在進行研究，並在多種癌症類型中顯示出前景。這些方法為個人化治療方法提供了新途徑，並可透過解決異質性腫瘤特徵和適應性抗藥性機制來改善患者預後。

在預測期內，大腸直腸癌領域的複合年成長率最高。

由於標靶治療的進步，預計結直腸癌領域在預測期內將出現最高的複合年成長率。這些抑制劑，如Cetuximab和Panitumumab，透過抑制 EGFR 訊號途徑，在改善患者預後方面顯示出有希望的結果。由於全球大腸直腸癌盛行率不斷上升以及對個人化治療的需求不斷增加，預計 EGFR 抑制劑市場將顯著成長。

比最大的地區

由於癌症發病率增加和標靶治療的進步等因素，預計北美在預測期內將佔據最大的市場佔有率。這些抑制劑專注於精準醫療，在肺癌和大腸癌等多種癌症的治療中發揮重要作用。該地區的主要公司繼續投資於研發，旨在推出創新治療方法。

複合年成長率最高的地區：

預計亞太地區在預測期內將維持最高的複合年成長率。該地區經常使用 EGFR 抑制劑治療的癌症（例如肺癌和大腸癌）的發生率正在增加。人們對癌症的認知不斷提高，篩檢計畫得到加強，從而能夠及早發現癌症，從而使更多的患者有資格接受標靶治療。此外，不斷上升的醫療保健成本和意識進一步推動市場成長，創造了以持續的臨床試驗和產品發佈為特徵的競爭格局。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球表皮生長因子受體（EGFR）市場：依類型

  • 單株抗體 (mAb)
  • 蛋白酪氨酸激酶抑制劑 (TKI)
  • 聯合治療
  • 其他類型

第6章全球表皮生長因子受體（EGFR）市場：依藥物類型

  • Erlotinib
  • Cetuximab
  • Gefitinib
  • Osimertinib
  • Afatinib
  • 其他藥物類型

第7章全球表皮生長因子受體（EGFR）市場：依管理模式

  • 口服
  • 靜脈

第8章全球表皮生長因子受體（EGFR）市場：按分銷管道

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章全球表皮生長因子受體（EGFR）市場：依應用分類

  • 非小細胞肺癌（NSCLC）
  • 胰臟癌
  • 大腸直腸癌
  • 頭頸癌
  • 其他用途

第 10 章全球表皮生長因子受體 (EGFR) 市場：依最終用戶分類

  • 醫院
  • 癌症治療中心
  • 學術研究所
  • 其他最終用戶

第11章全球表皮生長因子受體（EGFR）市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Merck & Co.
  • Amgen Inc
  • Eli Lilly and Company
  • OSI Pharmaceuticals Inc
  • Johnson & Johnson
  • Genentech, Inc
  • Pfizer
  • AstraZeneca PLC
  • Bayer AG
  • AbbVie
  • Bristol Myers Squibb
  • Teva Pharmaceutical Industries
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim
  • Regeneron Pharmaceuticals
Product Code: SMRC26275

According to Stratistics MRC, the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is accounted for $14.1 billion in 2024 and is expected to reach $31.4 billion by 2030 growing at a CAGR of 14.2% during the forecast period. Epidermal Growth Factor Receptor (EGFR) inhibitors are a class of medications that target the epidermal growth factor receptor, a protein found on the surface of cells. EGFR is involved in cell growth and division, and its overactivity is associated with the development and progression of certain types of cancer, particularly lung cancer and colorectal cancer. GFR inhibitors are used in the treatment of various cancers, either alone or in combination with other cancer therapies, such as chemotherapy or radiation therapy.

According to the NIH, the new cases of various types of major cancers, such as lung cancer, colorectal cancer, and breast cancer, in the US have increased significantly in recent years. In 2020, an estimated 1.8 million new cases of cancer were diagnosed in the US, and 606,520 people will die from the disease.

Market Dynamics:

Driver:

Growing adoption of targeted therapies

The market is witnessing a surge in adoption of targeted therapies, reflecting an evolving treatment landscape. Targeted therapies offer precision in combating cancer by specifically targeting cancer cells, minimizing damage to healthy tissue. This paradigm shift is driven by advancements in research and development, alongside increasing understanding of molecular pathways driving cancer progression. With personalized treatment approaches gaining traction, the market is poised for substantial growth as it moves towards tailored therapies for individual patients.

Restraint:

Availability of alternative therapies

The market faces challenges in accommodating alternative therapies. Despite the effectiveness of EGFR inhibitors, alternative treatments like immunotherapy and targeted therapies pose competition. Additionally, resistance to EGFR inhibitors and adverse effects contribute to the complexity. Ensuring accessibility, affordability, and patient awareness of alternative therapies remain key hurdles. The market must adapt by integrating these therapies into treatment protocols and addressing patient-specific needs for optimal outcomes.

Opportunity:

Rising cancer rates

The market has seen a concerning trend of rising cancer rates. Despite advancements in treatment utilizing EGFR inhibitors, such as Erlotinib and Gefitinib, the incidence of cancer cases reliant on these therapies has increased. This may indicate either a growing prevalence of EGFR-driven cancers or potential resistance development in patients previously responsive to these drugs. Such trends underscore the need for continued research into cancer biology and the development of innovative therapeutic strategies.

Threat:

High cost of treatment

The market faces challenges due to high treatment costs, posing a barrier to accessibility for patients. Despite their efficacy in treating certain cancers, the financial burden associated with these inhibitors limits their widespread adoption. This cost factor underscores the need for collaborative efforts among stakeholders to develop more affordable options or explore avenues for subsidization to ensure equitable access to life-saving treatments.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Market, causing disruptions in manufacturing, supply chains, and clinical trials. Lockdowns and restrictions hindered patient access to healthcare facilities, affecting diagnosis and treatment initiation. However, with the adoption of telemedicine and remote monitoring, some continuity was maintained. The market witnessed fluctuations in demand, with a shift towards prioritizing essential treatments. Despite challenges, ongoing research and development efforts persisted, aiming to address emerging needs and optimize therapeutic outcomes amidst the pandemic's challenges.

The combination therapies segment is expected to be the largest during the forecast period

The combination therapies segment is expected to be the largest during the forecast period. By targeting multiple pathways simultaneously, these therapies aim to enhance efficacy and overcome resistance mechanisms. Combinations of EGFR inhibitors with chemotherapy, immunotherapy, and other targeted agents are being explored, showing potential in various cancer types. Such approaches offer new avenues for personalized treatment regimens and may improve patient outcomes by addressing heterogeneous tumor profiles and adaptive resistance mechanisms.

The colorectal cancer segment is expected to have the highest CAGR during the forecast period

The colorectal cancer segment is expected to have the highest CAGR during the forecast period driven by advancements in targeted therapies. These inhibitors, such as cetuximab and panitumumab, have shown promising results in improving patient outcomes by inhibiting EGFR signaling pathways. With increasing prevalence of colorectal cancer globally, coupled with growing demand for personalized treatment approaches, the EGFR inhibitors market is poised for significant growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period driven by factors such as increasing cancer prevalence and advancements in targeted therapies. With a focus on precision medicine, these inhibitors play a crucial role in treating various cancers, including lung and colorectal cancer. Key players in the region continue to invest in research and development, aiming to introduce innovative therapies.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The region has witnessed a rise in the incidence of cancer, including lung cancer and colorectal cancer, which are often treated with EGFR inhibitors. Increasing awareness about cancer and the availability of screening programs have led to earlier detection of cancers, resulting in more patients being eligible for targeted therapies. Moreover, rising healthcare expenditure and awareness further bolster market growth, fostering a competitive landscape characterized by ongoing clinical trials and product launches.

Key players in the market

Some of the key players in Epidermal Growth Factor Receptor (EGFR) Inhibitors market include Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Amgen Inc, Eli Lilly and Company, OSI Pharmaceuticals Inc, Johnson & Johnson, Genentech, Inc, Pfizer, AstraZeneca PLC, Bayer AG, AbbVie, Bristol Myers Squibb, Teva Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim and Regeneron Pharmaceuticals.

Key Developments:

In May 2023, Eli Lilly and Innovent Biologics, Inc. jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT(R) (sintilimab injection) in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) in patients with epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC).

In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.

Types Covered:

  • Monoclonal Antibodies (mAbs)
  • Tyrosine Kinase Inhibitors (TKIs)
  • Combination Therapies
  • Other Types

Drug Types Covered:

  • Erlotinib
  • Cetuximab
  • Gefitinib
  • Osimertinib
  • Afatinib
  • Other Drug Types

Mode of Administration Covered:

  • Oral
  • Intravenous

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Non-Small Cell Lung Cancer (NSCLC)
  • Pancreatic Cancer
  • Colorectal Cancer
  • Head and Neck Cancer
  • Other Applications

End Users Covered:

  • Hospitals
  • Cancer Treatment Centers
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Epidermal Growth Factor Receptor (EGFR) Market, By Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies (mAbs)
  • 5.3 Tyrosine Kinase Inhibitors (TKIs)
  • 5.4 Combination Therapies
  • 5.5 Other Types

6 Global Epidermal Growth Factor Receptor (EGFR) Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Erlotinib
  • 6.3 Cetuximab
  • 6.4 Gefitinib
  • 6.5 Osimertinib
  • 6.6 Afatinib
  • 6.7 Other Drug Types

7 Global Epidermal Growth Factor Receptor (EGFR) Market, By Mode of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Intravenous

8 Global Epidermal Growth Factor Receptor (EGFR) Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Epidermal Growth Factor Receptor (EGFR) Market, By Application

  • 9.1 Introduction
  • 9.2 Non-Small Cell Lung Cancer (NSCLC)
  • 9.3 Pancreatic Cancer
  • 9.4 Colorectal Cancer
  • 9.5 Head and Neck Cancer
  • 9.6 Other Applications

10 Global Epidermal Growth Factor Receptor (EGFR) Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Cancer Treatment Centers
  • 10.4 Academic & Research Institutes
  • 10.5 Other End Users

11 Global Epidermal Growth Factor Receptor (EGFR) Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Novartis AG
  • 13.2 F. Hoffmann-La Roche Ltd
  • 13.3 Merck & Co.
  • 13.4 Amgen Inc
  • 13.5 Eli Lilly and Company
  • 13.6 OSI Pharmaceuticals Inc
  • 13.7 Johnson & Johnson
  • 13.8 Genentech, Inc
  • 13.9 Pfizer
  • 13.10 AstraZeneca PLC
  • 13.11 Bayer AG
  • 13.12 AbbVie
  • 13.13 Bristol Myers Squibb
  • 13.14 Teva Pharmaceutical Industries
  • 13.15 Takeda Pharmaceutical Company Limited
  • 13.16 Boehringer Ingelheim
  • 13.17 Regeneron Pharmaceuticals

List of Tables

  • Table 1 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Monoclonal Antibodies (mAbs) (2021-2030) ($MN)
  • Table 4 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Tyrosine Kinase Inhibitors (TKIs) (2021-2030) ($MN)
  • Table 5 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Combination Therapies (2021-2030) ($MN)
  • Table 6 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 8 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Erlotinib (2021-2030) ($MN)
  • Table 9 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Cetuximab (2021-2030) ($MN)
  • Table 10 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Gefitinib (2021-2030) ($MN)
  • Table 11 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Osimertinib (2021-2030) ($MN)
  • Table 12 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Afatinib (2021-2030) ($MN)
  • Table 13 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 14 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Mode of Administration (2021-2030) ($MN)
  • Table 15 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 17 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 18 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 19 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 20 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 21 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Application (2021-2030) ($MN)
  • Table 22 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Non-Small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 23 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Pancreatic Cancer (2021-2030) ($MN)
  • Table 24 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 25 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Head and Neck Cancer (2021-2030) ($MN)
  • Table 26 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 27 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By End User (2021-2030) ($MN)
  • Table 28 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
  • Table 30 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Academic & Research Institutes (2021-2030) ($MN)
  • Table 31 Global Epidermal Growth Factor Receptor (EGFR) Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.